Published in J Biol Chem on December 25, 1983
The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest (1984) 3.26
Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest (1998) 2.13
The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol (2009) 1.88
Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A (2008) 1.33
Leukotriene E4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. Proc Natl Acad Sci U S A (1984) 1.32
Leukotrienes in inflammation. Agents Actions (1986) 1.20
Leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes. Partial purification and identification as a cytochrome P-450. J Clin Invest (1985) 1.15
Leukotrienes in the sputum and urine of cystic fibrosis children. Br J Clin Pharmacol (1990) 1.10
Oxidative degradation of leukotriene C4 by human monocytes and monocyte-derived macrophages. J Exp Med (1985) 0.99
Modulation of leukotriene release from human polymorphonuclear leucocytes by PMA and arachidonic acid. Immunology (1988) 0.96
Dectin-2 regulates the effector phase of house dust mite-elicited pulmonary inflammation independently from its role in sensitization. J Immunol (2014) 0.89
Modulation of arachidonic and linoleic acid metabolites in myeloperoxidase-deficient mice during acute inflammation. Free Radic Biol Med (2010) 0.85
Effect of cations on leukotriene release: requirements for the metabolism of peptido-leukotrienes (leukotrienes C4, D4) by human polymorphonuclear granulocytes. Immunology (1986) 0.82
Acquisition of peroxidase activity by rat alveolar macrophages during pulmonary inflammation. Am J Pathol (1987) 0.81
Endogenous S-nitrosoglutathione modifies 5-lipoxygenase expression in airway epithelial cells. Am J Respir Cell Mol Biol (2006) 0.81
The role of arachidonic acid metabolites in local and systemic inflammatory processes. Drugs (1987) 0.79
Ascorbate in aqueous humor protects against myeloperoxidase-induced oxidation. Am J Pathol (1985) 0.78
Leukotriene A4 modulates generation of leukotriene B4 and sulphidopeptide leukotrienes by human neutrophils. Immunology (1992) 0.75
Cold urticaria: release into the circulation of histamine and eosinophil chemotactic factor of anaphylaxis during cold challenge. N Engl J Med (1976) 17.77
A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet (1997) 10.93
CARBOHYDRATE METABOLISM IN ADDISON'S DISEASE. J Clin Invest (1940) 9.89
Synthesis and activity of a new generation of ruthenium-based olefin metathesis catalysts coordinated with 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene ligands. Org Lett (1999) 9.01
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 8.58
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res (2004) 6.49
Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation (2004) 6.43
Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science (1997) 6.00
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol (1971) 5.41
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. Science (2001) 5.22
Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci U S A (1999) 5.08
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol (1969) 4.38
A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med (1971) 4.07
Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med (1990) 4.06
Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med (1985) 4.00
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
A neutrophil-immobilizing factor derived from human leukocytes. I. Generation and partial characterization. J Exp Med (1972) 3.75
Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature (2000) 3.61
The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung. J Immunol (1971) 3.51
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
THE EFFECT OF 17-HYDROXYCORTICOSTERONE AND RELATED ADRENAL CORTICAL STEROIDS ON SODIUM AND CHLORIDE EXCRETION. Science (1941) 3.45
Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology (2005) 3.44
Triggering myocardial infarction by marijuana. Circulation (2001) 3.36
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. J Exp Med (1972) 3.31
Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A (1983) 3.30
The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest (1984) 3.26
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol (1968) 3.24
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component. J Immunol (1967) 3.18
Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol (1983) 3.18
Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A (1980) 3.18
Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2) Am J Med Genet (1996) 3.17
Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med (2000) 3.12
The complement system of man. I. N Engl J Med (1972) 3.09
Antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-A) in the guinea pig and rat. J Exp Med (1967) 3.08
Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. Hum Mutat (2001) 3.07
A pre-albumin activator of prekallikrein. J Immunol (1970) 2.95
Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A (1980) 2.94
Molecular genetics of human blue cone monochromacy. Science (1989) 2.92
Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J Clin Invest (1974) 2.90
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol (1984) 2.85
Native heparin from rat peritoneal mast cells. J Biol Chem (1977) 2.79
Genotyping microarray (gene chip) for the ABCR (ABCA4) gene. Hum Mutat (2003) 2.75
Inactivation of slow reacting substance of anaphylaxis by human eosinophil arylsulfatase. J Immunol (1975) 2.73
Clinical diagnosis of the Usher syndromes. Usher Syndrome Consortium. Am J Med Genet (1994) 2.72
Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med (1987) 2.69
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol (1982) 2.69
An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med (1971) 2.65
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature (1992) 2.64
Computerized mappings of the cerebral cortex: a multiresolution flattening method and a surface-based coordinate system. J Cogn Neurosci (1996) 2.56
Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis. Proc Natl Acad Sci U S A (1975) 2.56
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. II. Influence of cellular levels of cyclic AMP. Fed Proc (1972) 2.55
Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with Bardet-Biedl syndrome. Nat Genet (2000) 2.53
The complement system in rheumatoid synovitis. I. An analysis of complement component activities in rheumatoid synovial fluids. Arthritis Rheum (1971) 2.53
Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun (1980) 2.49
Nobel laureates' letter to President Bush. Washington Post (2001) 2.43
Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature (1981) 2.41
Immunological release of histamine and slow-reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3',5'-adenosine monophosphate. J Exp Med (1971) 2.39
Tryptase from human pulmonary mast cells. Purification and characterization. J Biol Chem (1981) 2.37
The inhibitory effect of polysaccharides isolated from Phellinus linteus on tumor growth and metastasis. Immunopharmacology (1999) 2.36
The physicochemical characteristics and purification of slow-reacting substance of anaphylaxis. J Immunol (1973) 2.34
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Hereditary deficiency of the second component of complement (C'2) in man. J Clin Invest (1966) 2.32
The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med (1972) 2.31
Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet (1998) 2.31
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
Structure of leukotriene C. Identification of the amino acid part. Biochem Biophys Res Commun (1979) 2.30
Tumor-associated eosinophilotactic factor. N Engl J Med (1974) 2.27
Bardet-Biedl syndrome is linked to DNA markers on chromosome 11q and is genetically heterogeneous. Nat Genet (1994) 2.26
MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene (2010) 2.23
Slow reacting substance of anaphylaxis. Adv Immunol (1969) 2.23
Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci U S A (1975) 2.20
Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet (2001) 2.19
Inactivation of slow reacting substance of anaphylaxins (SRS-A) by arylsulfatases. J Immunol (1974) 2.19